BANZATO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.679
AS - Asia 541
EU - Europa 376
Continente sconosciuto - Info sul continente non disponibili 4
Totale 4.600
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.673
CN - Cina 305
SG - Singapore 121
IT - Italia 77
VN - Vietnam 75
FI - Finlandia 74
DE - Germania 62
SE - Svezia 53
GB - Regno Unito 39
FR - Francia 26
UA - Ucraina 20
KR - Corea 15
NL - Olanda 11
IN - India 10
CA - Canada 6
IE - Irlanda 5
JP - Giappone 5
EU - Europa 4
TW - Taiwan 4
BE - Belgio 3
RU - Federazione Russa 3
TR - Turchia 2
CZ - Repubblica Ceca 1
DK - Danimarca 1
HK - Hong Kong 1
IR - Iran 1
PK - Pakistan 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 4.600
Salva come PNG Salva come JPEG
Città #
Fairfield 635
Chandler 361
Woodbridge 351
Ashburn 338
Houston 327
Ann Arbor 260
Cambridge 219
Seattle 217
Wilmington 187
Beijing 97
Singapore 96
Jacksonville 90
Dong Ket 75
Princeton 75
San Diego 75
Roxbury 44
Nanjing 41
Medford 40
Des Moines 39
Helsinki 26
Boardman 25
Padova 23
Nanchang 17
Frankfurt am Main 15
New York 15
Santa Clara 15
Guangzhou 14
Shenyang 14
Hebei 13
Seoul 13
Hefei 9
London 9
Milan 8
Norwalk 7
Redwood City 7
Dallas 6
Detroit 6
Jiaxing 6
Jinan 6
Tianjin 6
Changsha 5
Dublin 5
Washington 5
Dearborn 4
Indiana 4
Kunming 4
Munich 4
Rome 4
Taichung 4
Tokyo 4
Brussels 3
Genoa 3
Ningbo 3
Ogden 3
Pune 3
Tappahannock 3
Zhengzhou 3
Bertinoro 2
Borås 2
Cherasco 2
Gandhinagar 2
Haikou 2
Hounslow 2
Kharkiv 2
Leipzig 2
Pescara 2
Prescot 2
Saint Louis 2
Shanghai 2
Taizhou 2
Verona 2
Vicenza 2
Aarhus 1
Bari 1
Buffalo 1
Cedar Falls 1
Chiswick 1
Chongqing 1
Clifton 1
Columbus 1
Den Haag 1
Downers Grove 1
Edinburgh 1
Falkenstein 1
Fragneto Monforte 1
Geislingen an der Steige 1
Grenoble 1
Islamabad 1
Islington 1
Lisbon 1
Marcallo con Casone 1
Montreal 1
Mussolente 1
Napoli 1
Orange 1
Pearland 1
Pusan 1
Quzhou 1
Riyadh 1
Rockville 1
Totale 3.949
Salva come PNG Salva come JPEG
Nome #
(188)Rhenium-induced cell death and apoptosis in a panel of tumor cell lines 142
A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. 134
Laboratory testing for antiphospholipid syndrome 127
Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate 125
Diagnosis and therapy of antiphospholipid syndrome 124
Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite Antiphospholipid Syndrome. 116
Interpretation of laboratory data and need for reference laboratories. 113
The Paradox of the Lupus Anticoagulant: History and Perspectives 113
A YAP camera for the biodistribution of Re-188 conjugated with Hyaluronic-Acid in "in vivo" systems 111
APS - Diagnostics and challenges for the future 110
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer 107
Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant 107
Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review 107
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. 105
Lupus anticoagulant testing: Diluted Russell Viper Venom Time (dRVVT) 105
Antiphospholipid syndrome: critical analysis of the diagnostic path 102
Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles 101
Novel types of carborane-carrier hyaluronan derivatives via "click chemistry". 98
Correct laboratory approach to APS diagnosis and monitoring 96
A paclitaxel-hyaluronan bioconjugate exerts a high in vivo therapeutic activity against ovarian cancer 95
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. 94
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 92
Bioavailability of Tc-99m-Ha-paclitaxel complex [Tc-99m-ONCOFID-P] in mice using four different administration routes 91
Hydrosoluble, Metabolically Fragile Bioconjugates by Coupling Tetrabutylammonium Hyaluronan with 2′ Paclitaxel-4-Bromobutyrate: Synthesis and Antitumor Properties 91
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial 91
Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk 88
Confirmation of the initial antiphospholipid antibody positivity depends on antiphospholipid antibody profile 87
Biokinetic and dosimetric studies of Re-188-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma 85
β2-Glycoprotein I Binds to Thrombin and Selectively Inhibits the Enzyme Procoagulant Functions 84
Detection of lupus anticoagulant in the era of direct oral anticoagulants 84
Secondary prevention in thrombotic antiphospholipid syndrome. 83
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 81
Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability 80
Laboratory Diagnostics of Antiphospholipid Syndrome 78
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. 78
Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. 77
Radiopharmacokinetic and dosimetric studies of Re-188-HA: comparison with Re-188-HDD/lipiodol 76
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis 76
The challenges of lupus anticoagulants 72
Risk-based secondary prevention of obstetric antiphospholipid syndrome. 70
Clinical Relevance of β2-Glycoprotein-I Plasma Levels in Antiphospholipid Syndrome (APS) 68
Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy 68
Beta 2 glycoprotein I selectively inhibits the procoagulant function of thrombin: a novel physiologic anticoagulant mechanism in haemostasis 64
What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? 63
A mouse model of liver metastasis 63
Preliminary data on the evaluation of Rhenium-188 in radiotherapy application Hyaluronic Acid as vector for liver neoplasies and DNA damage induced by 188Re in vitro systems 61
The role of platelets in antiphospholipid syndrome 61
PN2S-PEG-BIOMOLECULE DERIVATIVES LABELED WITH TECHNETIUM-99m IN ABSENCE OF AN EXTERNAL REDUCING AGENT 57
Chemical Synthesis and Characterization of Wild-type and Biotinylated N-terminal Domain 1-64 of Beta2-glycoprotein I 53
Identifying novel thrombin interactions: Alpha-synuclein binds to thrombin exosites and inhibits thrombin-mediated platelet aggregation 46
Radiopharmacokinetic and dosimetric studies of 188Re-HA: comparation with 188Re-HHD/lipiodol 43
Effect of anti beta2-glycoprotein I Lupus Anticoagulant antibodies on clotting time in the presence of human umbilical vein endothelial cells 42
Novel thrombin interactions: alpha-synuclein binds thrombin exosites and inhibits thrombin-mediated platelet aggregation 36
Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study 22
Totale 4.643
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.710
article - articoli 15.602
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.312
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020835 0 0 0 78 107 79 130 119 111 112 64 35
2020/2021574 39 42 23 43 15 54 35 50 86 38 41 108
2021/2022775 19 95 102 71 13 47 36 86 30 13 73 190
2022/2023642 129 83 10 73 106 78 0 52 67 7 28 9
2023/2024340 4 59 38 19 27 65 24 51 7 1 27 18
2024/2025199 8 69 79 43 0 0 0 0 0 0 0 0
Totale 4.643